These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 26467217

  • 1. A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression.
    Meng J, Liu Y, Gao S, Lin S, Gu X, Pomper MG, Wang PC, Shan L.
    Cancer Biol Ther; 2015; 16(12):1764-74. PubMed ID: 26467217
    [Abstract] [Full Text] [Related]

  • 2. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [Abstract] [Full Text] [Related]

  • 3. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
    Clin Cancer Res; 2013 Sep 01; 19(17):4717-27. PubMed ID: 23857604
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
    Zhou X, Qiu J, Wang Z, Huang N, Li X, Li Q, Zhang Y, Zhao C, Luo C, Zhang N, Teng X, Chen Z, Liu X, Yu X, Wu W, Wei YQ, Li J.
    J Cancer Res Clin Oncol; 2012 Jul 01; 138(7):1081-90. PubMed ID: 22392077
    [Abstract] [Full Text] [Related]

  • 5. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
    Naemi AA, Salmanian AH, Noormohammadi Z, Amani J.
    Eur J Pharmacol; 2023 Sep 15; 955():175894. PubMed ID: 37429519
    [Abstract] [Full Text] [Related]

  • 6. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
    Thomas Koch D, Pickhard A, Gebel L, Buchberger AMS, Bas M, Mogler C, Reiter R, Piontek G, Wirth M.
    Oncotarget; 2017 May 16; 8(20):32668-32682. PubMed ID: 28427242
    [Abstract] [Full Text] [Related]

  • 7. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y, Shimizu S, Shishido-Hara Y, Suzuki K, Shiokawa Y, Nagane M.
    Cancer Med; 2016 Mar 16; 5(3):486-99. PubMed ID: 26778701
    [Abstract] [Full Text] [Related]

  • 8. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.
    Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I.
    Proc Natl Acad Sci U S A; 1996 Dec 10; 93(25):14815-20. PubMed ID: 8962138
    [Abstract] [Full Text] [Related]

  • 9. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK, Shonka N.
    J Exp Clin Cancer Res; 2019 Jun 18; 38(1):266. PubMed ID: 31215502
    [Abstract] [Full Text] [Related]

  • 10. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
    Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, Gu J, Digiammarino EL, Palma JP, Donawho CK, Goodwin NC, Scott AM.
    Mol Cancer Ther; 2015 May 18; 14(5):1141-51. PubMed ID: 25731184
    [Abstract] [Full Text] [Related]

  • 11. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.
    Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG, McKay LM, Goodwin NC, Reilly EB.
    Mol Cancer Ther; 2016 Apr 18; 15(4):661-9. PubMed ID: 26846818
    [Abstract] [Full Text] [Related]

  • 12. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.
    Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, Plückthun A, Stahel RA, Zangemeister-Wittke U.
    Clin Cancer Res; 2003 Jul 18; 9(7):2837-48. PubMed ID: 12855664
    [Abstract] [Full Text] [Related]

  • 13. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H, Gao H, Kong J, Song B, Wang P, Shi B, Wang H, Li Z.
    Cancer Immunol Res; 2018 Nov 18; 6(11):1314-1326. PubMed ID: 30201736
    [Abstract] [Full Text] [Related]

  • 14. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
    Niesen J, Stein C, Brehm H, Hehmann-Titt G, Fendel R, Melmer G, Fischer R, Barth S.
    J Cancer Res Clin Oncol; 2015 Dec 18; 141(12):2079-95. PubMed ID: 25899161
    [Abstract] [Full Text] [Related]

  • 15. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG.
    Oncogene; 2014 Jan 23; 33(4):429-39. PubMed ID: 23376850
    [Abstract] [Full Text] [Related]

  • 16. Immunotoxin-mediated targeting of claudin-4 inhibits the proliferation of cancer cells.
    Hashimi SM, Yu S, Alqurashi N, Ipe DS, Wei MQ.
    Int J Oncol; 2013 Jun 23; 42(6):1911-8. PubMed ID: 23563899
    [Abstract] [Full Text] [Related]

  • 17. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
    Chandramohan V, Bao X, Yu X, Parker S, McDowall C, Yu YR, Healy P, Desjardins A, Gunn MD, Gromeier M, Nair SK, Pastan IH, Bigner DD.
    J Immunother Cancer; 2019 May 29; 7(1):142. PubMed ID: 31142380
    [Abstract] [Full Text] [Related]

  • 18. Novel EGFR‑bispecific recombinant immunotoxin based on cucurmosin shows potent anti‑tumor efficiency in vitro.
    Zhang C, Cai Y, Dai X, Wu J, Lan Y, Zhang H, Lu M, Liu J, Xie J.
    Oncol Rep; 2021 Feb 29; 45(2):493-500. PubMed ID: 33416157
    [Abstract] [Full Text] [Related]

  • 19. [The research on construction and expression of eukaryotic expression plasmid for a recombinant immunotoxin mMIP-1alpha-DT390].
    Lü ML, Li H, Liang WB, Chen WJ, Jia Y, Jiang ZH, Zhang WD, Zhang L.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jan 29; 38(1):1-5. PubMed ID: 17294715
    [Abstract] [Full Text] [Related]

  • 20. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso Iii JC, Kaur B, Caligiuri MA, Yu J.
    Sci Rep; 2015 Jul 09; 5():11483. PubMed ID: 26155832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.